UPDATE 3-AmerisourceBergen sees $60 mln hit from troubled Memphis plant
Operations at the automated facility in Memphis, its largest, were suspended in December following an inspection by the U.S. drug regulator. The plant, which makes medicines in doses that are not commercially available, was acquired as part of AmerisourceBergen's 2015 buy of PharMEDium Healthcare Holdings.
from Biotech News
0 Comments